49,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 49,000 shares of the biopharmaceutical company's stock, valued at approximately $462,000.

Several other institutional investors have also bought and sold shares of the stock. Xponance Inc. raised its holdings in Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 2,249 shares in the last quarter. KBC Group NV grew its position in Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 3,120 shares in the last quarter. Swiss National Bank increased its holdings in shares of Amicus Therapeutics by 0.7% during the 4th quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock valued at $4,121,000 after acquiring an additional 3,200 shares during the last quarter. Legacy Capital Group California Inc. raised its stake in shares of Amicus Therapeutics by 20.2% in the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock valued at $219,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Amicus Therapeutics in the 3rd quarter worth approximately $55,000.

Analyst Upgrades and Downgrades

FOLD has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Wells Fargo & Company decreased their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $16.75.

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded down $0.43 during mid-day trading on Tuesday, reaching $6.72. The stock had a trading volume of 4,582,349 shares, compared to its average volume of 2,552,128. Amicus Therapeutics, Inc. has a one year low of $6.62 and a one year high of $12.65. The firm has a market cap of $2.06 billion, a PE ratio of -37.33, a P/E/G ratio of 1.51 and a beta of 0.79. The firm's 50 day simple moving average is $8.95 and its 200 day simple moving average is $9.76. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.